Great Plains Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Noninvasive Assessment of Myocardial Fibroblast Activation May Improve Phenotyping, Risk Stratification For HFrEF
  Persistent activation of myocardial fibroblasts was observed in patients with heart failure with reduced ejection fraction (HFrEF), with distinct spatial patterns related to the etiology of the cardiomyopathy, according to results from a prospective study published April 15 in JAMA Cardiology.
• Eagle’s Eye View: Can BP Control Trajectories Lead to Better CV Outcomes?
  In this week’s Eagle's Eye View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis.
• OCEANIC-STROKE: Asundexian Lowers Recurrent Stroke Risk in Patients With Noncardioembolic Stroke or TIA
  Asundexian lowered the risk of ischemic stroke and major cardiovascular events, without increasing the risk of major bleeding, in patients with noncardioembolic stroke or high-risk transient ischemic attack (TIA) taking antiplatelet therapy, according to results from the phase 3, double-blind OCEANIC-STROKE trial, published April 15 in NEJM.
• LEFT-BUNDLE-CRT: Is LBBAP Noninferior to BiVP For CRT?
  Among patients who were eligible for CRT, left bundle branch area pacing (LBBAP) was not found to be noninferior to biventricular pacing (BiVP) in the intention-to-treat analysis, according to results from the LEFT-BUNDLE-CRT trial published April 14 in EHJ.
• Current Evidence and Strategies to Address Sex Hormone-Associated Thrombotic and CV Risk
  The influences of sex hormone therapy – for contraception, treatment of heavy menstrual bleeding, hormone-replacement therapy, gender-affirming care therapy, etc. – on venous thrombotic and cardiovascular risk was explored in a Review Article published April 15 in NEJM.